Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin
delivery and diabetes technology company, today announced
publication by the New England Journal of Medicine (NEJM) of
results from the landmark Protocol 3 study (DCLP3) of the National
Institutes of Health (NIH)-funded International Diabetes Closed
Loop (iDCL) trial using the t:slim X2™ insulin pump with
Control-IQ™ advanced hybrid closed-loop technology. The DCLP3 study
was the first-ever large-scale, six-month closed-loop study that
included a dedicated control group. Over the six-month study
period, use of Control-IQ technology led to a higher percentage of
time spent in range (70-180 mg/dL), less hyper- and hypoglycemia
and better HbA1c levels than use of a sensor augmented pump. No
severe hypoglycemic events were reported, and 100 percent of
participants completed the study. The article was published today
on the journal website, NEJM.org, and will appear in the October
31, 2019 printed issue.
The t:slim X2 insulin pump with Control-IQ technology, currently
under review by the U.S. Food and Drug Administration (FDA),
utilizes Dexcom G6 continuous glucose monitoring (CGM) sensor
values to predict glucose levels 30 minutes ahead and adjust
insulin delivery to help prevent highs and lows, while still
allowing the user to manually bolus for meals. The system also
delivers automatic correction boluses, which is a feature not
commercially available today on automated insulin delivery
devices.
“This NEJM publication recognizes the importance and rigor of
the landmark DCLP3 study and the robustness of the safety and
efficacy data behind the t:slim X2 insulin pump with Control-IQ
technology,” said John Sheridan, president and CEO of Tandem
Diabetes Care. “These outcomes, combined with the overwhelmingly
positive experiences reported by trial participants, give us
confidence that availability of Control-IQ technology will further
our mission to improve the lives of people with diabetes, and we
continue to prepare for its commercial launch this year, pending
FDA approval.”
“We are thrilled with the results published today and proud of
the role Dexcom played in the DCLP3 study,” said Kevin Sayer,
Chairman, President and Chief Executive Officer at Dexcom.
“Consistent use and exceptional sensor accuracy are critical
components for optimized glucose control in an advanced hybrid
closed loop system. As the study’s greater than 90 percent average
time in closed loop demonstrates, Dexcom’s G6 excels on both of
these fronts. The integration of Control-IQ technology with
Dexcom’s G6 has proven to be a powerful combination for automated
insulin delivery.”
Key Data Highlights
Glycemic Control over Six Months
- Time in range (70 mg/dL – 180 mg/dL) increased from 61 percent
at baseline to 71 percent using Control-IQ technology. The control
group using sensor-augmented pump therapy alone, remained unchanged
at 59 percent (p<0.0001). This mean difference amounted to 2.6
more hours per day spent in the target range.
- Time in range at night (midnight to 6:00 a.m.) was 76 percent
using Control-IQ technology compared to 59 percent using a
sensor-augmented pump (p<0.0001).
- Time spent below 70 mg/dL was 1.6 percent using Control-IQ
technology compared to 2.3 percent using a sensor-augmented pump
(p<0.001). No severe hypoglycemia was reported.
- Time spent above 180 mg/dL was 27 percent using Control-IQ
technology compared to 38 percent using a sensor-augmented pump
(p<0.001).
- Statistically significant improvements in HbA1c and reductions
in mean glucose were observed.
System Performance and Usability
- The median time the system was in active closed-loop mode was
over 90 percent
- The median time the Dexcom G6 CGM was in use was 97
percent
- 100 percent of participants completed the study
The NIH-funded DCLP3 study was a 6-month, randomized
multi-center study that included a dedicated control group.
Following a two to eight-week run-in period, the length of which
was determined based on previous pump and CGM experience, 168
patients with type 1 diabetes ages 14 and up were randomized 2:1 to
Control-IQ technology (n=112) or sensor-augmented pump (SAP)
therapy (n=56) and followed for 26 weeks. The entry HbA1c for
participants in the study ranged from 5.4 to 10.6 with a mean of
7.4 percent. Approximately 20 percent of participants were new to
pump therapy and the large majority were already using a CGM. All
participants completed the study. There were no exclusion criteria
based on hemoglobin A1c (HbA1c), history of acute complications, or
previous experience using an insulin pump or CGM.
The iDCL trial was funded by the NIH’s National Institute of
Diabetes and Digestive and Kidney Diseases under grant
DK108483.
Reference:
Brown SA, Kovatchev D, Raghinaru JW, et al. Six-Month
Randomized, Multicenter Trial of Closed-Loop Control in Type 1
Diabetes. N Engl J Med. 2019;381(18):1707-17. DOI:
10.1056/NEJMoa1907863
About the t:slim X2 Insulin Pump
The simple-to-use t:slim X2 insulin pump includes advanced
features like a large color touchscreen, rechargeable battery,
Bluetooth® wireless technology, USB connectivity and watertight
construction (IPX7)1. It is capable of remote software updates
using a personal computer, offering the potential for users to
access new features as they meet necessary regulatory
requirements.2 The t:slim X2 pump is up to 38 percent smaller than
other insulin pumps and holds up to 300 units of insulin.3 The
t:slim X2 pump was the first insulin pump classified by the FDA in
a new device category called alternate controller enabled (ACE)
infusion pumps and the first system approved as compatible with
interoperable continuous glucose monitoring (iCGM) devices.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical
device company dedicated to improving the lives of people with
diabetes through relentless innovation and revolutionary customer
experience. Tandem takes an innovative, user-centric approach to
the design, development and commercialization of products for
people with diabetes who use insulin. Tandem’s flagship product,
the t:slim X2 insulin pump, is capable of remote software updates
using a personal computer and features integrated continuous
glucose monitoring. Tandem is based in San Diego, California.
Tandem Diabetes Care is a registered trademark, and t:slim X2
and Control-IQ are trademarks of Tandem Diabetes Care, Inc. Dexcom
and Dexcom G6 are registered trademarks of Dexcom, Inc. The
Bluetooth word mark and logos are registered trademarks owned by
Bluetooth SIG, Inc. and any use of such marks by Tandem Diabetes
Care, Inc. is under license. All other third-party marks are the
property of their respective owners.
Forward Looking Statement
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, that concern matters that involve risks and uncertainties
that could cause actual results to differ materially from those
anticipated or projected in the forward-looking statements. These
forward-looking statements relate to, among other things, the
anticipated commercial launch of the t:slim X2 insulin pump with
Control-IQ technology, the timing and outcome of regulatory
approvals for the t:slim X2 with Control-IQ technology, and the
ability of our products to improve customer satisfaction and
clinical outcomes. These statements are subject to numerous risks
and uncertainties, including the risks that regulatory agencies may
fail to approve new product features or updates on our expected
timeframe or at all, the real-world clinical benefits from use of
Control-IQ technology may not match the results reported in the
DCLP3 study and the level of customer satisfaction from the use of
our products and features may be different from what we expect. In
addition, we rely on numerous third-party suppliers, partners and
licensors for the commercialization of the t:slim X2 with
Control-IQ. Any disruption or delays by any of these third parties
may adversely impact our commercial launch goals. We also may
experience other risks identified in Tandem’s most recent Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q,
respectively, and other documents we file with the Securities and
Exchange Commission. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this release. Tandem undertakes no obligation to
update or review any forward-looking statement in this press
release because of new information, future events or other
factors.
1 Tested to a depth of 3 feet for 30 minutes 2 Future algorithms
and integrations with compatible devices may not be developed, and
would be subject to applicable regulatory requirements. A
prescription and additional training may be required to access
certain future software updates. Charges may apply. 3 38 percent
smaller than MiniMed 630G and 670G and at least 28 percent smaller
than MiniMed 530G, Animas Vibe and Omnipod System. Data on file,
Tandem Diabetes Care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191016005902/en/
Tandem Diabetes Care Contact Information: Media: Steve
Sabicer, (714) 907-6264, ssabicer@thesabicergroup.com Investors:
Susan Morrison, (858) 366-6900 x7005,
smorrison@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Sep 2023 to Sep 2024